Labcorp (LH) has made substantial strides in recent years, as indicated by the significant investor interest. Strs Ohio, Czech National Bank, Strathmore Capital Advisors, Signature Estate & Investment Advisors, Select Equity Group and MBB Public Markets have all invested in shares of Labcorp. The company has raised its annual profit gauge due to robust
diagnostic testing demand. The company announces its Q2 results in 2025, exceeding revenue expectations but falling short on EPS. Furthermore, executives at Labcorp are selling substantial shares, hinting at potential weakness. With a view to expanding its reach in cancer diagnostics, Labcorp made a significant move by purchasing certain assets of BioReference Health's oncology, contributing in revenue surges of approximately 25.6% this year. The company's CEO cited a 'very healthy' deal pipeline amidst rumors of M&A. It has stayed in the limelight for its FDA-approved blood test for Alzheimer's, changing its investment story. Labcorp has introduced
Test Finder, a unique AI tool that simplifies lab test searches, displaying its innovative approach to diagnostic searchability. Despite some misses, Labcorp's financial performance has been robust overall, with share prices hitting a 52-week high of $258.7 recently.
Laboratory Corporation of America Holdings LH News Analytics from Sat, 19 Oct 2024 07:00:00 GMT to Fri, 19 Sep 2025 13:31:15 GMT -
Rating 8
- Innovation 5
- Information 8
- Rumor -4
